Additionally, we found mutations in other well-known tumor suppressor genes such as STK11 and CDKN2A. In the lung adenocarcinoma manuscript from TCGA, mutations in STK11 and CDKN2A were reported in 17% and 4% of all patients, respectively [14]. This evidence concerns the gene CDKN2A and neoplasm.